Core Viewpoint - The potential separation of Samsung's foundry business from its semiconductor division is being considered to address ongoing concerns about conflicts of interest and to improve its competitive position in the market [1][2]. Group 1: Business Separation and Market Position - Samsung Biologics announced the complete separation of its contract development and manufacturing (CDMO) business from its biosimilar business, prompting speculation about a similar move for Samsung's semiconductor foundry business [1]. - The foundry business, while the second largest globally, has struggled to secure orders, partly due to concerns from major tech companies about potential leaks of design technology [2]. - Analysts suggest that separating the foundry could alleviate these conflicts and provide an opportunity to escape significant financial losses, potentially leading to a listing on the NASDAQ [2]. Group 2: Internal Restructuring and Future Directions - The System LSI division has been under comprehensive review due to ongoing technical challenges and declining profitability, with decisions regarding its future expected soon [2]. - There is speculation that the mobile application processor team within the System LSI division may merge with the mobile experience division, which could increase the likelihood of foundry separation [3]. - If the System LSI division does not merge with the mobile experience division, the next consideration would be merging with the foundry division, as collaboration between design and production is deemed essential for success in advanced processes [3].